When the world gets closer.

We help you see farther.

Sign up to our expressly international daily newsletter.

blog

The King's Door

The King's Door

Glimpsing through the crack of the imposing brass doors was as much as we were going to see of the Royal Palace of Fes: Visitors are (still) unfortunately not allowed in.


See more slides from My Grand-Père's World.

You've reached your limit of free articles.

To read the full story, start your free trial today.

Get unlimited access. Cancel anytime.

Exclusive coverage from the world's top sources, in English for the first time.

Insights from the widest range of perspectives, languages and countries.

Coronavirus

As COVID Explodes, An Inside Look At China's Gray Market Of Generic Drugs

COVID infections have skyrocketed since China eased restrictions as public health policy has not been able to keep up. Unable to find medications, many have turned to generic drugs of questionable safety. It's the culmination of a longstanding problem.

Photo of a pharmarcist walking past shelves with medication in Yucheng, northern China

A pharmacy in Yucheng, northern China

Xian Zhu and Feiyu Xiang

BEIJING — When her grandfather joined the millions of infected Chinese, Chen quickly decided to buy COVID-19 drugs to limit the effects of the virus. She woke up early to shop on Jingdong, one of China’s biggest online shopping websites, but failed in snatching the limited daily stocks made available.

Fearing COVID's effect on her grandfather, who suffers from dementia, she contacted an independent drug agent and bought a box of generic pharmaceuticals.

With China having suddenly ended its zero-COVID policy, infections have peaked. According to the latest estimates by Airfinity, a British medical information and analysis company, severe COVID outbreaks happened over Chinese New Year with 62 million infections forecast for the second half of January.

In a press conference held by China's State Council on Jan. 11, COVID-19 pills were mentioned as part of the new epidemic control mechanisms. In late 2021, Pfizer developed Paxlovid, the world's first potent COVID drug, with one 100 mg white ritonavir and two 150 mg light pink nirmatrelvir tablets taken every 12 hours. China imported the first batch of Paxlovid for clinical use in March 2022 and included it in the ninth edition of the treatment protocol.

But the first 21,200 boxes of Paxlovid were dispersed to only eight provinces, and no further information is available on where the drug ended up and how much it was used.

Keep reading...Show less

You've reached your limit of free articles.

To read the full story, start your free trial today.

Get unlimited access. Cancel anytime.

Exclusive coverage from the world's top sources, in English for the first time.

Insights from the widest range of perspectives, languages and countries.

The latest